Companies /Healthcare
Novartis AG ADR
NYSE: NVS Drug Manufacturers - General
$140.79
▼ $0.14 (−0.10%) today
Markets closed · 2:46am ET

Novartis (NVS) Q1 2026 Earnings

Reported Apr 28, 2026, 6:21am ET · SEC source
$1.99
Miss −3.68%
EPS · est. $2.07
$13.1B
Miss −2.72%
Revenue · est. $13.5B
−3.1%
Trailing market
NVS vs S&P since report
1 quarter
Consecutive EPS misses

How Did NVS Stock React to Q1 2026 Earnings?

% change · around the report
0+2%+4%Apr 28Apr 29report 6:21am ETearnings−0.5%+2.5%
0+2%+4%Apr 28Apr 29earnings−0.5%+2.5%
NVS +2.5%S&P 500 −0.5%
0+2%+4%Apr 28Apr 29report 6:21am ETearnings−0.2%+2.5%
0+2%+4%Apr 28Apr 29earnings−0.2%+2.5%
NVS +2.5%NASDAQ −0.2%
0+2%+4%+6%Apr 27May 6report 6:21am ETearnings+2.3%+5.1%
0+2%+4%+6%Apr 27May 6earnings+2.3%+5.1%
NVS +5.1%S&P 500 +2.3%
0+2%+4%+6%Apr 27May 6report 6:21am ETearnings+4.8%+5.1%
0+2%+4%+6%Apr 27May 6earnings+4.8%+5.1%
NVS +5.1%NASDAQ +4.8%
+0.91%
Day of report
−1.76%
Next session
+0.00%
One week
+3.21%
30 days

S&P 500 over the same 30 days: +6.29%.

Did NVS Beat Earnings? Q1 2026 Results

No. Novartis reported Q1 2026 earnings of $1.99 a share on Apr 28, 2026, missing the $2.07 consensus estimate by 3.7%. Revenue was $13.1B against a $13.5B estimate.

Novartis delivered a mixed first quarter for 2026, posting earnings per share of $1.99 on revenue of $13.11 billion as robust growth from newer therapies failed to fully offset steep declines across legacy franchises hit by generic competition. Net sales slipped 1% in USD and 5% in constant currencies year-over-year, with the quarter's defining tension laid bare in the stark contrast between old and new: Entresto tumbled 42% to $1.30 billion following US generic entry, while Kisqali surged 59% to $1.52 billion and Pluvicto climbed 73% to $642 million on strong demand in pre-taxane mCRPC. Core operating margin contracted 4.8 percentage points to 37.3%, reflecting both the revenue headwinds and elevated R&D costs tied to the $12 billion Avidity Biosciences acquisition that closed in February, a deal that pushed net debt sharply higher to $38.09 billion. Free cash flow held broadly stable at $3.33 billion, offering some reassurance that the business retains meaningful underlying financial resilience despite the earnings pressure.

Key Takeaways
  • Kisqali strong growth driven by early breast cancer indication and continued mBC leadership
  • Pluvicto continued strong demand in pre-taxane mCRPC setting in the US
  • Kesimpta growth across all regions driven by increased demand and strong access as high-efficacy B-cell therapy for RMS
  • Scemblix momentum in early-line CML setting with 64 markets having secured approvals
  • Leqvio acceleration ex-US driven by China NRDL inclusion in January 2026
  • Generic competition negatively impacting Entresto, Promacta/Revolade, and Tasigna
  • Volume contributed 13 percentage points to growth, offset by 14 percentage points of generic competition
  • Currency had positive 4 percentage point impact on net sales

NVS YoY Financials

Revenue$13.1B
Gross Profit$10.1B
Operating Income$4.2B
Net Income$3.2B

NVS Revenue by Segment

Entresto$1.3B−42.0%
Cosentyx$1.6B+2.0%
Kisqali$1.5B+59.0%
Kesimpta$1.2B+29.0%
Pluvicto$642.0M+73.0%
Promacta/Revolade$184.0M−66.0%
Tafinlar + Mekinist$493.0M−11.0%
Jakavi$557.0M+13.0%

NVS Revenue by Geography

Rest of World
United States$5.0B−13.0%
Europe$4.2B+7.0%
Asia Pacific
China$1.3B+13.0%
Americas

When Does Novartis Report Next?

Expected report date
Before the open
Release timing

Figures from SEC filings and company reports. Not investment advice.